{"id":"NCT02015234","sponsor":"Tonix Pharmaceuticals, Inc.","briefTitle":"12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients","officialTitle":"A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2013-12-19","resultsPosted":"2017-07-07","lastUpdate":"2017-07-07"},"enrollment":158,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Fibromyalgia"],"interventions":[{"type":"DRUG","name":"TNX-102 SL","otherNames":["cyclobenzaprine HCl"]}],"arms":[{"label":"TNX-102 SL","type":"EXPERIMENTAL"}],"summary":"This was an open-label, extension trial designed to evaluate the long-term safety over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of fibromyalgia. Patients recruited into this trial were those who had successfully completed the double-blind study, TNX-CY-F202 (F202) (NCT01903265). Patients were not made aware of the therapy they received during the double-blind study.","primaryOutcome":{"measure":"Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia.","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Placebo - TNX-102 SL 2.8 mg","deltaMin":60,"sd":null},{"arm":"TNX-102 SL 2.8 mg - TNX-102 SL 2.8 mg","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":79},"commonTop":["Hypoaesthesia oral","Sinusitis","Fatigue","Product taste abnormal","Glossodynia"]}}